No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

Table 3

Cox proportional hazard regression model analysis of overall survival.

Overall survival
Covariate	HR (95% CI)
Age	1.04 (1.01-1.07)	0.02
Genetic risk (ELN 2010)	1.4(1.03-1.85)	0.03
CD33 genotypes	0.8 (0.4-1.5)	0.5

Abbreviations: ELN: European Leukemia; CI: confidence interval.